PET probes of small molecule polypeptide immunosuppressive agents guiding tumor immunotherapy

doi:10.3760/cma.j.issn.1673-422X.2019.08.001

Abstract

Abstract: Immunosuppressant targeting programmed death protein-1 and its ligand (PD-1/PD-L1) is a hot topic in solid tumor immunotherapy. Detection of PD-1/PD-L1 expression in solid tumor patients by molecular imaging can predict whether tumor patients can benefit from immunotherapy. Small molecular polypeptide inhibitors have the advantages of low molecular weight, fast diffusion in tumor microenvironment, uniform distribution and easy access to the deep part of solid tumor. Non-invasive, real-time and quantitative detection of PD-1/PD-L1 expression in tumor patients can be performed by radionuclide labeled small molecular polypeptide inhibitor molecular probe PET imaging. It is expected to provide new detection methods for patient screening, efficacy monitoring, treatment plan optimization and prognosis evaluation.

Key words: Immunosuppressive agents, Positron-emission tomography, Immunotherapy

Jiang Jinquan, Liu Teli, Xia Lei, Zhu Hua, Yang Zhi. PET probes of small molecule polypeptide immunosuppressive agents guiding tumor immunotherapy[J]. Journal of International Oncology, 2019, 46(8): 449-452.

References

［1］ Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer［J］. Nat Rev Clin Oncol, 2014, 11(1): 24-37. DOI: 10.1038/nrclinonc.2013.208. ［2］ Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1positive advanced gastric cancer (keynote-012): a multicentre, open-label, phase 1b trial［J］. Lancet Oncol, 2016, 17(6): 717-726. DOI: 10.1016/S1470-2045(16)00175-3. ［3］ Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ono-4538-12, attraction-2): a randomised, double-blind, placebo-controlled, phase 3 trial［J］. Lancet, 2017, 390(10111): 2461-2471. DOI: 10.1016/S0140-6736(17)31827-5. ［4］ Gandini S, Massi D, Mandala M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematicreview and meta-analysis［J］. Crit Rev Oncol Hematol, 2016, 100: 88-98. DOI: 10.1016/j.critrevonc.2016.02.001. ［5］ Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer［J］. N Engl J Med, 2012, 366(26): 2443-2454. DOI: 10.1056/NEJMoa1200690. ［6］ Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy［J］. Clin Cancer Res, 2014, 20(19): 5064-5074. DOI: 10.1158/1078-0432.CCR-13-3271. ［7］ Chatterjee S, Lesniak WG, Gabrielson M, et al. A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors［J］. Oncotarget, 2016, 7(9): 10215-10227. DOI: 10.18632/oncotarget.7143. ［8］ Natarajan A, Mayer AT, Reeves RE, et al. Development of novel immunoPET tracers to image human PD-1 checkpoint expression on tumor-infiltrating lymphocytes in a humanized mouse model［J］. Mol Imaging Biol, 2017, 19(6): 903-914. DOI: 10.1007/s11307-017-1060-3. ［9］ Hettich M, Braun F, Bartholoma MD, et al. High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers［J］. Theranostics, 2016, 6(10): 1629-1640. DOI: 10.7150/thno.15253. ［10］ Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer［J］. Lab Invest, 2014, 94(1): 107-116. DOI: 10.1038/labinvest.2013.130. ［11］ Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells［J］. PLoS One, 2014, 9(2): e88557. DOI: 10.1371/journal.pone.0088557. ［12］ Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway［J］. N Engl J Med, 2016, 375(18): 1767-1778. DOI: 10.1056/NEJMra1514296. ［13］ Shukuya T, Mori K, Amann JM, et al. Relationship between overall survival and response or progression-free survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 antibodies［J］. J Thorac Oncol, 2016, 11(11): 1927-1939. DOI: 10.1016/j.jtho.2016.07.017. ［14］ Tumeh PC, Hellmann MD, Hamid O, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and nsclc［J］. Cancer Immunol Res, 2017, 5(5): 417-424. DOI: 10.1158/2326-6066.CIR-16-0325. ［15］ Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma［J］. Blood, 2017, 130(10): 1189-1197. DOI: 10.1182/blood-2017-03-775122. ［16］ Lipson EJ, Forde PM, Hammers HJ, et al. Antagonists of PD-1 and PD-L1 in cancer treatment［J］. Semin Oncol, 2015, 42(4): 587-600. DOI: 10.1053/j.seminoncol.2015.05.013. ［17］ Puri S, Chatwal M, Gray JE. Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents［J］. Expert Rev Respir Med, 2017, 11(10): 791-805. DOI: 10.1080/17476348.2017.1361323. ［18］ Wang X, Teng F, Kong L, et al. PD-L1 expression in human cancers and its association with clinical outcomes［J］. Onco Targets Ther, 2016, 9: 5023-5039. DOI: 10.2147/OTT.S105862. ［19］ Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy［J］. Lancet Oncol, 2016, 17(12): e542-e551. DOI: 10.1016/S1470-2045(16)30406-5. ［20］ Niemeijer AN, Leung D, Huisman MC, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer［J］. Nat Commun, 2018, 9(1): 4664. DOI: 10.1038/s41467-018-07131-y. ［21］ Bensch F, van der Veen EL, Lubde Hooge MN, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer［J］. Nat Med, 2018, 24(12): 1852-1858. DOI: 10.1038/s41591-018-0255-8. ［22］ Chatterjee S, Lesniak WG, Miller MS, et al. Rapid PD-L1 detection in tumors with PET using a highly specific peptide［J］. Biochem Biophys Res Commun, 2017, 483(1): 258-263. DOI: 10.1016/j.bbrc.2016.12.156. ［23］ De Silva RA, Kumar D, Lisok A, et al. Peptide-based 68Ga-PET radiotracer for imaging PD-L1 expression in cancer［J］. Mol Pharm, 2018, 15(9): 3946-3952. DOI: 10.1021/acs.molpharmaceut.8b00399. ［24］ Abdel-Magid AF. Inhibitors of the PD-1/PD-L1 pathway can mobilize the immune system: an innovative potential therapy for cancer and chronic infections［J］. Acs Med Chem Lett, 2015, 6(5): 489-490. DOI: 10.1021/acsmedchemlett.5b00148. ［25］ Zak KM, Grudnik P, Guzik K, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)［J］. Oncotarget, 2016, 7(21): 30323-30335. DOI: 10.18632/oncotarget.8730. ［26］ Guzik K, Zak KM, Grudnik P, et al. Smallmolecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1［J］. J Med Chem, 2017, 60(13): 5857-5867. DOI: 10.1021/acs.jmedchem.7b00293. ［27］ Skalniak L, Zak KM, Guzik K, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of t-cells［J］. Oncotarget, 2017, 8(42): 72167-72181. DOI: 10.18632/oncotarget.20050.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[6]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[7]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[8]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Guo Ciliang, Jiang Chunping, Wu Junhua. Gut microbiome and tumor immunotherapy [J]. Journal of International Oncology, 2023, 50(7): 432-436.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[13]	Gu Anqin, Long Jinhua, Jin Feng. Clinical research progress of immunotherapy for nasopharyngeal carcinoma [J]. Journal of International Oncology, 2023, 50(5): 299-303.
[14]	Ding Hao, Ying Jintao, Fu Maoyong. Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(4): 231-235.
[15]	Ma Pengcheng, Chen Yu. Research progress of primary pulmonary lymphoepithelioma-like carcinoma [J]. Journal of International Oncology, 2023, 50(3): 174-178.